-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAX-1 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAX-1 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAX-1 in Metastatic Breast Cancer Drug Details: PAX-1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAX-1 in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAX-1 in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAX-1 in Non-Small Cell Lung Carcinoma Drug Details: PAX-1 is...
-
Product Insights
Paxareiras (Pax) II D&E
Paxareiras (Pax) II D&E is an Onshore Wind project located in Galicia, Spain. The project is owned by Acciona Energia SA and was developed by EUROVENTO, S.L.; Eurus Energy UK Ltd. The project came online in 2002. Empower your strategies with our Paxareiras (Pax) II D&E report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Company Insights
Innovation and Patenting activity of PAX Global Technology Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PAX Global Technology Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAX-1 in Metastatic Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PAX-1 in Metastatic Prostate Cancer Drug Details: PAX-1 is under development for the treatment of...
-
Thematic Analysis
NewWeb3 – Thematic Intelligence
Web3 is an ideology that refers to the next iteration of the internet built on blockchain. It promises a mix of peer-to-peer (P2P) communication channels and decentralized governance, leading the internet’s transition from an information-centric model to a user-centric model. Web3 aims to give users the ability to create, own, and monetize their content and manage the use of their data. This will be stored on blockchains instead of on third-party servers.
-
Thematic Analysis
Payments Sector Scorecard – Thematic Intelligence
Payments Sector Scorecard Thematic Intelligence Report Overview Disruptive solutions such as blockchain, AI, and cloud technology are driving changes in the payments industry. Companies such as JPMorgan Chase, GoogleC, Visa, and Mastercard are heavily investing in these solutions even though they are at their early stage of using disruptive technologies. In addition, incumbent companies acquire startups and stakes in competitors to grow their market share. Fintech startups first showed interest in new payment solutions such as open banking, blockchain, and...
-
Product Insights
Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) - Drugs In Development, 2023’, provides an overview of the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Encephalomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Encephalomyelitis - Drugs In Development, 2023’, provides an overview of the Encephalomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...